
    
      Patients are randomized to receive either hard gel or soft gel capsules of saquinavir in
      combination with at least one licensed nucleoside antiretroviral. Treatment will continue for
      48 weeks. After the first 16 weeks, patients will be given the opportunity to roll over to
      the saquinavir formulation of choice.
    
  